The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksDestiny Pharma. Share News (DEST)

Share Price Information for Destiny Pharma. (DEST)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 15.75
Bid: 15.50
Ask: 16.00
Change: 0.00 (0.00%)
Spread: 0.50 (3.226%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 15.75
DEST Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

UK TRADING UPDATE SUMMARY: Codemasters On Up As Finds Right Formula

Tue, 11th Aug 2020 12:36

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Tuesday and not separately reported by Alliance News:

----------

Codemasters Group Holdings PLC - Warwickshire-based video game developer - Revenue and adjusted earnings before interest, tax, depreciation and amortisation will be "significantly" ahead of market expectations in year to March 31, 2021. Codemasters notes strong performance from F1 2020 game, latest instalment of Formula One games.

----------

Parity Group PLC - London-based recruitment and professional services firm - Signs partnership agreement with CyberGym to offer cyber-warfare preparedness training. The due win a place on the NI.CO Cyber Security Training Services Framework to provide consultancy and recruitment support in Northern Ireland.

----------

Actual Experience PLC - Bath-headquartered analytics-as-a-service firm - Lands agreement with Verizon Communications Inc to supply its Human Experience Management service to increase employee productivity. Service can spot when digital applications are unresponsive and slow and can identify where improvements can be made.

----------

Solid State PLC - Worcestershire-based computing products manufacturer - Trading in first four months of financial year running to March 31, 2021 ahead of internal expectations. Revenue down 4% annually. Notes all manufacturing sites open again.

----------

Blue Star Capital PLC - esports and payments technology-focused investor - Investee Dynasty eSports Pte Ltd raises SGD3.1 million, about GBP1.7 million, to develop eSports Portal Management platform.

----------

Pires Investments PLC - London-based technology-focused investment firm - Investee Getvisibility signs public sector distribution deal with immixGroup, supplier of enterprise IT services to US public sector.

----------

Two Shields Investments PLC - investor in technology sector - BrandShield cyber protection investee sees new business in first half of 2020 alone equal all of 2019 as Covid-19 boosts demand. Has 11% stake in BrandShield. Also notes announcement by Power Metal Resources PLC - an exploration and development company - on Kalahari Key Mineral Exploration Ltd. KKME, targeting a nickel sulphide prospects in Botswana, is moving closer to drilling and is working with regulators to secure approval of an environmental plan. Power Metal holds just over an 18% stake in KKME, Two Shields holding is just shy of 18%.

----------

McKay Securities PLC - real estate investment trust focused on office, industrial and logistics properties - Acquires fully let logistics asset in Bracknell for GBP10.0 million, representing a net initial yield of 5.6%. Combined contracted rent at 1-4 Willoughby Road is GBP594,722 per year.

----------

Urban Logistics REIT PLC - real estate investment trust focused on industrial and logistics properties in UK - Acquires three assets in Colchester, Exeter and Nottingham for GBP36.8 million in total. Also enters into GBP151 million loan facility with Barclays, Santander and Lloyds to replace existing GBP76 million facility, which was due to expire in 2022. New facility has a three-year term with an option to extend by an extra two-years.

----------

Phoenix Spree Deutschland Ltd - investment company focused on Berlin residential real estate - Portfolio value at June 30 up 2.3% to EUR746.7 million from EUR730.2 million at end of December. Impact of Covid-19 on rent collection has been "limited". Says it is likely that Mietendeckel, a rent capping law in Berlin, will be successfully challenged.

----------

Gunsynd PLC - London-based investment firm - Notes investee Eagle Mountain Mining Ltd begins maiden drilling programme at 80%-owned Oracle Ridge copper mine near Tucson, Arizona.

----------

Cadence Minerals PLC - mineral resources investment company - Amapa iron ore project owner DEV Mineracao SA in constructive dialogue with creditors. Settlement with creditors remains the last precondition before Cadence takes 20% stake in project, located in Brazil.

----------

Westmount Energy Ltd - South America-focused energy investor - Notes Monday announcement by Ratio Petroleum Energy Ltd Partnership that Stena Carron drillship arrived at the Tanager-1 wellsite on the Kaieteur Block, offshore Guyana with drilling expected to kick off "imminently". Westmount holds roughly 0.7% stake in Ratio Petroleum and about 5.4% interest in Cataleya Energy Corp. Ratio and Cataleya hold 25% interest each in Kaieteur.

----------

Panther Metals PLC - Australia and Canada-focused minerals explorer - Finds a total of 253 geophysical anomalies from airborne survey of Big Bear gold project in Ontario, Canada. Notes 39 of 253 anomalies designated as "high-priority".

----------

Salt Lake Potash Ltd - Australia-focused miner - Set to raise AUD98.5 million, about GBP54.0 million, from combination of institutional share offer and retail entitlement offer. Raises AUD71 million from issue of 142.1 million shares as part of institutional offer, while AUD27 million retail entitlement offer is expected to close on August 25.

----------

Pure Gold Mining Inc - Canada-focused gold miner - Reports forest fire is currently active in town just south of Red Lake mine, Ontario. Pure Gold has temporarily suspended operations at mine.

----------

Great Western Mining Corp PLC - mineral explorer with projects in US state of Nevada - Produces first ever gold as a company. Although a small amount, Great Western hails the gold produced from RH Group area of its Mineral County area in Nevada as a "significant milestone".

----------

Shefa Gems Ltd - gemstone explorer in northern Israel - Receives ILS330,000, about GBP74,057, and 313,000 shares in major shareholder Shefa Yamim Ltd to settle debt. Shefa Gems has agreed not to sell Shefa Yamim shares in the market for a period of six months, which started July 20.

----------

Conroy Gold & Natural Resources PLC - gold explorer in Ireland and Finland - Raises GBP800,000 in placing and subscription of 3.2 million shares at 25 pence each. Including exercise of warrants announced in July, Conroy has secured over GBP1.0 million to bolster working capital.

----------

OptiBiotix Health PLC - York-based life sciences company - Results from peer-reviewed studies show its probiotic LPLDL reduces cholesterol and blood pressure. One study showed a 37% fall in total cholesterol and a 5.1% decline in blood pressure.

----------

RUA Life Sciences PLC - Ayrshire, Scotland-based medical device business - Hospital orders recovered from Covid-19 lows faster in US than Europe. US orders now at 90% of pre-pandemic levels, Europe at 67%. Notes furloughed staff have returned to work.

----------

Destiny Pharma PLC - clinical stage biotechnology firm - Safety review of phase 2b clinical trial of lead asset XF-73 completed by independent committee. Study can continue without any recommended changes and recruitment on track to be completed by end of 2020.

----------

Sareum Holdings PLC - drug developer focused on small molecule therapeutics to improve cancer and autoimmune treatment - Expects annual loss on ordinary activities to narrow to GBP960,000 from GBP1.5 million.

----------

Hemogenyx Pharmaceuticals PLC - pre-clinical stage biopharmaceutical firm headquartered in London - Enters into research pact with University of Pennsylvania to advance its chimeric antigen receptor T-cells towards clinical trial. CAR T-cells being developed for potential treatment of acute myeloid leukaemia.

----------

Fusion Antibodies PLC - pharmaceutical company based in Belfast - Notes partner Queens University Belfast awarded GBP50,000 in funding to develop new schemes to boost life science research in Northern Ireland.

----------

Cairn Homes PLC - Dublin-based housebuilder - Revenue in six months to June 30 down about 58% to roughly EUR80.6 million from EUR192.4 million a year earlier. New home sales down 47% to 207 from 390. Operating profit expected to fall 79% to about EUR5.6 million from EUR27.3 million.

----------

Modern Water PLC - London-based water supply company - Expects 2019 results to be released by end of month following audit delays.

----------

S & U PLC - Solihull-based lender focused on motor finance and property bridging - Sales at Advantage Finance recover to nearly 80% of normal levels as more car sales outlets reopen. Advantage sales were previously as low as 40% of normal levels. Loan applications at record high at Advantage but transaction levels 25% less than last year due to tightened underwriting. Aspen benefits from housing sector reopening with new transactions in July being above budget.

----------

Appreciate Group PLC - Liverpool-based multi-retailer - Completes sale of Budworth Properties Ltd unit which owns Valley Road, Birkenhead land and buildings for GBP3.2 million.

----------

Walker Greenbank PLC - Buckinghamshire-based interior furnishings firm - Total brand sales, before licensing, discounts and rebates, in six months to July 31 down 28% annually. In UK, its largest market, sales down 31%. In international arm, sales fell 24%. Notes early pain from Covid-19 but gained momentum as half ended.

----------

By Eric Cunha; ericcunha@alliancenews.com

Copyright 2020 Alliance News Limited. All Rights Reserved.

More News
22 Dec 2022 11:25

Destiny Pharma on track for commercial agreement for NTCD-M3 drug

(Alliance News) - Destiny Pharma PLC on Thursday said partnering negotiations for its NTCD-M3 clinical programme are nearing finalisation.

Read more
7 Dec 2022 17:35

Destiny Pharma eyes potential billion dollar returns from Nasal asset

(Alliance News) - Destiny Pharma PLC on Wednesday said it has finalised development plans for phase three testing of its late-stage clinical asset, XF-73 Nasal, which aims to prevent post-surgical staphylococcal infections.

Read more
7 Dec 2022 16:27

Destiny Pharma finalises plans for next study of its lead asset

(Sharecast News) - Biotechnology company Destiny Pharma has finalised plans for phase-three studies of its late-stage clinical asset 'XF-73 Nasal', it announced on Wednesday.

Read more
15 Nov 2022 16:16

Destiny Pharma starts new drug study for its skin infection treatment

(Alliance News) - Destiny Pharma PLC on Tuesday said it had started a safety study to enable its XF-73 treatment to be labelled as an Investigational New Drug.

Read more
15 Nov 2022 12:53

Destiny Pharma starts new safety study of dermal formulation

(Sharecast News) - Biotechnology developer Destiny Pharma announced the start of an investigational new drug (IND)-enabling safety study with its novel 'XF-73 Dermal' formulation.

Read more
8 Sep 2022 15:17

Destiny Pharma loss widens, pins hope on late stage clinical assets

(Alliance News) - Destiny Pharma PLC on Thursday reported a widened interim loss, as it progresses two key clinical assets.

Read more
7 Sep 2022 17:21

Destiny Pharma gets positive EMA feedback for gut bacteria treatment

(Alliance News) - Destiny Pharma PLC on Wednesday announced that it had received positive feedback from the European Medicine Agency on its NTCD-M3 phase 3 development plans.

Read more
7 Sep 2022 08:06

Destiny Pharma receives 'positive feedback' from EMA on NTCD-M3

(Sharecast News) - Clinical stage biotechnology company Destiny Pharma has received "positive feedback" from the European Medicine Agency regarding the proposed Phase III development programme of its new antibiotic treatment.

Read more
1 Sep 2022 15:59

UK earnings, trading statements calendar - next 7 days

Friday 2 September 
Ashmore Group PLCFull Year Results
Monday 5 September 
Belvoir Group PLCHalf Year Results
Dechra Pharmaceuticals PLCFull Year Results
Tuesday 6 September 
Accrol Group Holdings PLCFull Year Results
Alumasc Group PLCFull Year Results
Ashtead Group PLCQ1 Results
Capricorn Energy PLCHalf Year Results
Gamma Communications PLCHalf Year Results
Headlam Group PLCHalf Year Results
Inspired PLCHalf Year Results
IQE PLCHalf Year Results
Lords Group Trading PLCHalf Year Results
Luceco PLCHalf Year Results
Michelmersh Brick Holdings PLCHalf Year Results
Midwich Group PLCHalf Year Results
NCC Group PLCFull Year Results
PCI-PAL PLCFull Year Results
Pebble Group PLCHalf Year Results
Quixant PLCHalf Year Results
STV Group PLCHalf Year Results
WAG Payment Solutions PLCHalf Year Results
WANdisco PLCHalf Year Results
Wednesday 7 September 
Bakkavor Group PLCHalf Year Results
Barratt Developments PLCFull Year Results
Equals Group PLCHalf Year Results
M Winkworth PLCHalf Year Results
Malin Corp PLCHalf Year Results
Petropavlovsk PLCHalf Year Results
Somero Enterprises IncHalf Year Results
Tissue Regenix Group PLCHalf Year Results
WH Smith PLCTrading Statement
Thursday 8 September 
Arecor Therapeutics PLCHalf Year Results
Cairn Homes PLCHalf Year Results
Curtis Banks Group PLCHalf Year Results
Darktrace PLCFull Year Results
Destiny Pharma PLCHalf Year Results
Duke Royalty LtdFull Year Results
Emis Group PLCHalf Year Results
Energean PLCHalf Year Results
Funding Circle Holdings PLCHalf Year Results
Genus PLCFull Year Results
International Public Partnerships LtdHalf Year Results
Melrose Industries PLCHalf Year Results
Mpac Group PLCHalf Year Results
Oakley Capital Investments LtdHalf Year Results
Open Orphan PLCHalf Year Results
Restaurant Group PLCHalf Year Results
Safestore Holdings PLCQ3 Results
Severfield PLCFull Year Results
Shield Therapeutics PLCHalf Year Results
SourceBio International PLCHalf Year Results
Spire Healthcare Group PLCHalf Year Results
Sylvania Platinum LtdFull Year Results
Vistry Group PLCHalf Year Results
  
Copyright 2022 Alliance News Limited. All Rights Reserved.

Read more
26 Jul 2022 22:16

TRADING UPDATES: De La Rue cancels contract; Apollon buys in Jamaica

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Tuesday and not separately reported by Alliance News:

Read more
19 Jul 2022 20:01

TRADING UPDATES: Capital backs outlook; Northcoders trades well

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Tuesday and not separately reported by Alliance News:

Read more
12 Jul 2022 15:39

Destiny Pharma awarded Cystic Fibrosis Foundation project

(Sharecast News) - Clinical-stage biotechnology company Destiny Pharma has received an award from the Cystic Fibrosis Foundation, it announced on Tuesday.

Read more
12 Jul 2022 12:07

IN BRIEF: Destiny Pharma receives undisclosed grant for MRSA study

Destiny Pharma PLC - Brighton-based clinical-stage biotechnology company - Receives undisclosed grant from Maryland-based non profit Cystic Fibrosis Foundation for a study on its drug candidate XF-73 on disease-causing bacteria MRSA.

Read more
7 Jul 2022 20:38

IN BRIEF: Destiny Pharma XF-73 shown to enhance activity of two drugs

Destiny Pharma PLC - Brighton-based clinical-stage biotechnology company - New data on its XF-73 drug show that it can boost the effectiveness of current standard of care antibiotics when used in combinational therapy. The new in-vitro data stemmed from experiments by studies at the School of Dentistry, Cardiff University, for the potential for XF-based drugs to enhance the effectiveness of key antibacterial treatments. When combined with polymyxin B, a last resort antibacterial drug used to treat life-threatening lung bacterial infections, XF-73 enhanced polymyxin B potency against Pseudomonas aeruginosa, a top priority WHO bacterial pathogen, by 4-fold, the research found.

Read more
5 Jul 2022 11:43

IN BRIEF: Destiny Pharma begins research on XF-73 for oral mucositis

Destiny Pharma PLC - Brighton-based clinical-stage biotechnology company - Starts new research programme in the US on oral mucositis, an inflammation of the mouth that is a common side effect of chemotherapy and radiotherapy. Firm tests its experimental drug candidate XF-73 as potential preventive medicine to ease suffering from oral mucositis. Explains that XF-73 has shown unique antimicrobial properties in phase 2 clinical trials.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.